- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:42 | Enliven Therapeutics stock target raised to $40 at H.C. Wainwright | 1 | Investing.com | ||
| Mi | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update | 38 | PR Newswire | Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June
EHA abstract reported cumulative MMR rate... ► Artikel lesen | |
| Mi | Enliven reports positive Phase 1 trial data for ELVN-001 in CML | 1 | Investing.com | ||
| ENLIVEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress | 40 | PR Newswire | Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to precedent... ► Artikel lesen | |
| 13.03. | Enliven Therapeutics GAAP EPS of -$0.46 | 1 | Seeking Alpha | ||
| 13.03. | Enliven Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.03. | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update | 609 | PR Newswire | Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues
Expected monotherapy and combination data from the ELVN-002 Phase 1... ► Artikel lesen | |
| 13.03. | Enliven Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 13.03. | Enliven Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.11.24 | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update | 263 | PR Newswire | Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,804 | -2,84 % | Valneva: Aktie trotzt negativen News | Die Aktie von Valneva kann sich auch zum Wochenstart gut behaupten. Trotz negativer News zum Chikungunya-Impfstoff IXCHIQ ist das Papier im Tagesverlauf auf der Handelsplattform Tradegate ins Plus gedreht.... ► Artikel lesen | |
| BIOFRONTERA | 2,620 | -1,13 % | An Overview of Biofrontera's Earnings | ||
| CRISPR THERAPEUTICS | 31,600 | -1,25 % | Are Investors Making a Big Mistake Dumping Shares of CRISPR Therapeutics? | ||
| BLUEBIRD BIO | 4,420 | -0,90 % | bluebird bio, Inc. - 10-Q, Quarterly Report | ||
| AFFIMED | 0,530 | -100,00 % | Affimed N.V.: Affimed Announces Receipt of Nasdaq Delisting Notice | MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced... ► Artikel lesen | |
| SORRENTO THERAPEUTICS | - | - | Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025 | US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly... ► Artikel lesen | |
| FATE THERAPEUTICS | 0,853 | -1,00 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates | Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June ... ► Artikel lesen | |
| DENALI THERAPEUTICS | 12,500 | 0,00 % | Denali Therapeutics shares fall after price target cut to $32 | ||
| CELLECTIS | 1,300 | 0,00 % | Cellectis Reports Financial Results for the First Quarter 2025 | Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma... ► Artikel lesen | |
| AGIOS | 24,600 | -3,15 % | Agios Pharmaceuticals, Inc.: Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress | ||
| VOYAGER THERAPEUTICS | 2,814 | -1,68 % | Voyager Therapeutics, Inc.: Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced... ► Artikel lesen | |
| UNIQURE | 11,390 | +0,44 % | uniQure Inc.: uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress | ~ AMT-130 granted Breakthrough Therapy designation by FDA ~
~ Initial safety data from third cohort of Phase I/II study show AMT-130 continues to be generally well-tolerated, with no treatment-related... ► Artikel lesen | |
| ENZO BIOCHEM | 0,436 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM XETRA - 30.04.2025 | The following instruments on XETRA do have their last trading day on 30.04.2025Die folgenden Instrumente in XETRA haben ihren letzten Handelstag am 30.04.2025ISIN NameCH0347556901 PFBK SCHW.HYP. 17-25... ► Artikel lesen | |
| SCILEX | 4,040 | -10,42 % | Scilex Holding Co - 10-Q, Quarterly Report | ||
| TECTONIC THERAPEUTIC | 20,220 | +1,76 % | Tectonic Therapeutic, Inc. - 10-Q, Quarterly Report |
ENLIVEN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,510 (-2,56 %) liegt der Kurs bei 19,380 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ENLIVEN THERAPEUTICS INC finden Sie auf Wallstreet Online.